Healthcare Services

Global Liraglutide And Semaglutide Industry Trends and Market Growth Forecast for 2026–2030

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Liraglutide And Semaglutide Market Across 2026–2030?

The market size for liraglutide and semaglutide has experienced rapid expansion in recent years. This market is projected to grow from $16.94 billion in 2025 to $18.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. The historical growth can be attributed to several factors, including the increasing prevalence of type 2 diabetes mellitus, the limitations of traditional antidiabetic therapies, growing obesity rates, the clinical success of injectable glp-1 drugs, and rising awareness of cardiovascular risk reduction.

The liraglutide and semaglutide market size is projected to experience substantial expansion over the upcoming years. It is expected to grow to $28.98 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.3%. This anticipated growth during the forecast period is attributable to the broadening indications for obesity treatment, an increasing demand for convenient dosing methods, the rising adoption of oral semaglutide, a heightened focus on holistic metabolic care, and elevated healthcare spending on the management of chronic diseases. Prominent trends throughout this period include the increasing uptake of GLP-1 receptor agonists for diabetes management, the expanding application of GLP-1 therapies in obesity treatment, a growing preference for once-weekly injectable treatments, the proliferation of oral GLP-1 formulations, and a continuous rise in their long-term use for glycemic and weight control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

What Primary Drivers Are Shaping The Development Of The Liraglutide And Semaglutide Market?

The escalating prevalence of diabetic patients is projected to fuel expansion within the liraglutide and semaglutide markets. Diabetes is a chronic health issue defined by elevated blood sugar levels, stemming from the body’s insulin resistance or inadequate insulin production. The increasing count of individuals with diabetes is linked to inactive lifestyles, poor dietary choices, and genetic factors. Liraglutide and semaglutide are vital for managing diabetic patients, offering effective control over blood glucose levels and minimizing the likelihood of associated complications. For example, in June 2024, the National Health Service, a UK government department, reported that in 2023, over half a million (549,000) new individuals in England were identified as being at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP, to 3,615,330. This figure marks a substantial increase compared to 3,065,825 in 2022, indicating a rise of nearly 20%. Hence, the growing population of diabetic patients is a key driver for the liraglutide and semaglutide markets.

What Segmentation Levels Are Considered In The Liraglutide And Semaglutide Market?

The liraglutide and semaglutide market covered in this report is segmented –

1) By Type: Pills, Liquid

2) By Administration: Parenteral, Oral

3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

How Are Trends Impacting The Liraglutide And Semaglutide Market?

Leading companies in the liraglutide and semaglutide markets are actively developing anti-diabetic biosimilar drugs, aiming to enhance glucose management and diminish cardiovascular risks for diabetic individuals. Anti-diabetic biosimilars represent economical, nearly identical renditions of original diabetes biologics, engineered to deliver the same health benefits. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical firm, introduced a biosimilar of the widely used anti-diabetic drug, Liraglutide, for the first time within India. This specific biosimilar of Liraglutide is an anti-diabetic medication designed to improve glycemic control among adults with type 2 diabetes mellitus. This launch effectively lowers daily therapy expenditures, considerably expanding nationwide access for a greater number of patients. Priced at approximately INR 100 for a standard 1.2 mg daily dose, it significantly cuts therapy costs by about 70% and requires a prescription for purchase.

Which Leading Firms Are Contributing To The Growth Of The Liraglutide And Semaglutide Market?

Major companies operating in the liraglutide and semaglutide market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals Plc, Viatris Inc., Amneal Pharmaceuticals Inc., Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited

Read the full liraglutide and semaglutide market report here:

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

How Does The Liraglutide And Semaglutide Market Perform Across Major Global Regions?

North America was the largest region in the liraglutide and semaglutide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liraglutide And Semaglutide Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

Browse Through More Reports Similar to the Global Liraglutide And Semaglutide Market 2026, By The Business Research Company

Semaglutides Global Market Report

https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report

Liraglutide Global Market Report

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Antiglaucoma Drugs Market

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795